U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07430592) titled 'Phase 2b Trial Combination of SJ733 Malaria' on Feb. 18.
Brief Summary: The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the effect. SJ733 will be administered in a 1-, 2-, or 3-day treatment schedule in combination with a single dose of tafenoquine.
Study Start Date: March 20
Study Type: INTERVENTIONAL
Condition:
Malaria
Malaria Vivax
Radical Cure
Intervention:
DRUG: SJ733/TQ placebo
SJ733 combined wit...